Inhibition of functional osteoblasts with the platelet-derived growth factor receptor (PDGFR) inhibitor imatinib mesylate in androgen-independent prostate cancer (PCa).

被引：0
|
作者：
Mathew, P [1 ]
Yang, J [1 ]
Kim, SJ [1 ]
Fidler, I [1 ]
Bucana, C [1 ]
Troncoso, P [1 ]
Wang, X [1 ]
Thall, P [1 ]
Logothetis, C [1 ]
Navone, N [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4625
引用
收藏
页码：413S / 413S
页数：1
相关论文
共 50 条
  • [41] Imatinib is active in glioblastoma multiforme expressing platelet-derived growth factor receptor
    Katz, Artur
    Barrios, Carlos Henrique
    Abramoff, Rober
    Simon, Sergio Daniel
    Gansl, Rene Claudio
    Tabacof, Jaques
    Viola, Fabiana
    EINSTEIN-SAO PAULO, 2008, 6 (02): : 115 - 119
  • [42] Platelet-derived growth factor receptor-β (PDGFRβ) in the breast metastatic tumor microenvironment
    Sizemore, Gina
    Mathur, Anisha
    Thies, Katie
    Bolyard, Chelsea
    Sizemore, Steven
    Kladney, Raleigh
    Trimboli, Anthony
    Kaur, Balveen
    Leone, Gustavo
    Ostrowski, Michael
    CANCER RESEARCH, 2016, 76
  • [43] Both platelet-derived growth factor receptor (PDGFR)-α and PDGFR-β promote murine fibroblast cell migration
    Yu, JH
    Moon, A
    Kim, HRC
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 282 (03) : 697 - 700
  • [44] A role of androgen receptor protein in cell growth of an androgen-independent prostate cancer cell line
    Furutani, T
    Takeyama, KI
    Koutoku, H
    Ito, S
    Taniguchi, N
    Suzuki, E
    Kudoh, M
    Shibasaki, M
    Shikama, H
    Kato, S
    BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 2005, 69 (11) : 2236 - 2239
  • [45] Marked response to imatinib mesylate in a patient with platelet-derived growth factor receptor beta-associated acute myeloid leukemia
    Yoshimitsu Shimomura
    Hayato Maruoka
    Takayuki Ishikawa
    International Journal of Hematology, 2017, 105 : 697 - 701
  • [46] Marked response to imatinib mesylate in a patient with platelet-derived growth factor receptor beta-associated acute myeloid leukemia
    Shimomura, Yoshimitsu
    Maruoka, Hayato
    Ishikawa, Takayuki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 105 (05) : 697 - 701
  • [47] LEF1 in Androgen-Independent Prostate Cancer: Regulation of Androgen Receptor Expression, Prostate Cancer Growth, and Invasion
    Li, Yirong
    Wang, Longgui
    Zhang, Miao
    Melamed, Jonathan
    Liu, Xiaomei
    Reiter, Robert
    Wei, Jianjun
    Peng, Yi
    Zou, Xuanyi
    Pellicer, Angel
    Garabedian, Michael J.
    Ferrari, Anna
    Lee, Peng
    CANCER RESEARCH, 2009, 69 (08) : 3332 - 3338
  • [48] Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans
    Rubin, BP
    Schuetze, SM
    Eary, JF
    Norwood, TH
    Mirza, S
    Conrad, EU
    Bruckner, JD
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) : 3586 - 3591
  • [49] Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor β-gene
    Bastie, JN
    Garcia, I
    Terré, C
    Cross, NCP
    Mahon, FX
    Castaigne, S
    HAEMATOLOGICA, 2004, 89 (10) : 1263 - 1264
  • [50] Platelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers
    Appiah-Kubi, Kwaku
    Wang, Ying
    Qian, Hai
    Wu, Min
    Yao, Xiaoyuan
    Wu, Yan
    Chen, Yongchang
    TUMOR BIOLOGY, 2016, 37 (08) : 10053 - 10066
12345